本文已被：浏览 572次 下载 522次
Received:October 31, 2021 Published Online:May 20, 2022
Received:October 31, 2021 Published Online:May 20, 2022
中文摘要: 双膦酸盐类药物（BPs）是治疗骨质疏松症及糖尿病性骨质疏松的一线和最具成本效益的药物。但至今各研究数据表明，BPs对糖代谢（糖尿病风险和胰岛素敏感性）的影响尚不明确。本文将对其研究进展作一综述，为BPs治疗糖尿病合并骨质疏松症提供参考依据。
Abstract:Bisphosphonates (BPs) are the first-line and cost-effective drugs for the treatment of osteoporosis and diabetes-induced osteoporosis. However, data from various studies have shown that the effects of BPs on glucose metabolism (diabetes risk and insulin sensitivity) are unclear. This article reviews its research progress and further provide evidence for BPs in the treatment of diabetes mellitus combined with osteoporosis.
文章编号： 中图分类号： 文献标志码：A
基金项目:山西省卫生健康委员会科研基金资助项目（2020067）；山西省回国留学人员科研资助项目（2017-121）
| Author Name | Affiliation |
| YAO Yao*， ZHU Yi-kun | *Department of Endocrinology, The Second Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030001, China |
| 朱亦堃2 | 2. 山西医科大学第二医院内分泌科，山西 太原 030001 |
| Author Name | Affiliation |
| YAO Yao*， ZHU Yi-kun | *Department of Endocrinology, The Second Clinical College of Shanxi Medical University, Taiyuan, Shanxi 030001, China |
| 朱亦堃2 | 2. 山西医科大学第二医院内分泌科，山西 太原 030001 |
引用文本：